SELLAS Life Sciences is a late-stage biopharmaceutical company developing novel cancer immunotherapies for a broad range of cancer indications.
The Company has a license agreement with Memorial Sloan-Kettering Cancer Center for its lead candidate, galinpepimut-S, which targets malignancies and tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen.
The WT1 antigen is one of the most widely expressed cancer antigens, ranked by the National Cancer Institute as the number 1 target for immunotherapy, with potential to treat more than 25+ cancers. Traditional approaches have not been able to address the WT1 protein.
The US Food and Drug Administration has granted orphan drug and fast track designations to galinpepimut-S for Acute Myeloid Leukemia and Malignant Pleural Mesothelioma, while the European Medicines Agency has granted orphan designations for AML and MPM.
Galinpepimut-S has the potential to complement current therapies by destroying residual tumor cancer cells in remission and providing ongoing immune surveillance to avoid or significantly delay cancer recurrence. The treatment has shown positive survival and safety trends in phase II trials, not found in standard of care therapies. In 2017, galinpepimut-S will enter Phase III trials for Acute Myeloid Leukemia and Malignant Pleural Mesothelioma in the U.S. and Europe.
SELLAS’ cancer programs also target other diverse indications in hematological cancers and solid tumors, with Phase I and Phase II trials underway in ovarian cancer and multiple myeloma, and plans for future trials in Chronic Myelogenous Leukemia and Glioblastoma Multiforme.
In addition to its partnership with Memorial Sloan-Kettering, SELLAS has a Cooperative Research and Development Agreement with the US National Heart, Lung and Blood Institute, National Institutes of Health.
Founded in 2012, SELLAS is headquartered in Hamilton, Bermuda, with additional offices in New York. The management team has a proven track record of developing and commercializing drugs and cancer therapeutics, taking companies public, out-licensing drug candidates, forming R&D partnerships, and creating multiple alliances with centers of excellence.